GlaxoSmithKline (GSK) has submitted a regulatory application in the EU for umeclidinium monotherapy, an investigative once-daily medicine used in patients with chrinic obstructive pulmonary disease (COPD).
The treatment, which is administered using the company's Ellipta inhaler, is designed to relive symptoms in adult suffers of COPD.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
-
How high earners could boost their pension by thousands and cut childcare costsSalary sacrifice could boost your pension by thousands, while also helping you save on childcare costs. We delve into the numbers.
-
Monzo launches 11 ETFs via Blackrock to help savers investMonzo customers can now invest BlackRock's iShares ETF range via its banking app, making investing more accessible to millions
